NeuroSense Therapeutics Ltd.
NRSN
$1.14
-$0.0301-2.57%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 06/30/2024 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.09M | 1.09M | 685.00K | 1.18M | 1.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.35M | 2.35M | 1.77M | 3.03M | 3.65M |
| Operating Income | -2.35M | -2.35M | -1.77M | -3.03M | -3.65M |
| Income Before Tax | -2.35M | -2.35M | -1.80M | -857.00K | -1.76M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.35M | -2.35M | -1.80M | -857.00K | -1.76M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.35M | -2.35M | -1.80M | -857.00K | -1.76M |
| EBIT | -2.35M | -2.35M | -1.77M | -3.03M | -3.65M |
| EBITDA | -2.34M | -2.34M | -1.77M | -3.02M | -3.65M |
| EPS Basic | -0.09 | -0.09 | -0.08 | -0.05 | -0.13 |
| Normalized Basic EPS | -0.06 | -0.06 | -0.05 | -0.03 | -- |
| EPS Diluted | -0.09 | -0.09 | -0.08 | -0.05 | -0.13 |
| Normalized Diluted EPS | -0.06 | -0.06 | -0.05 | -0.03 | -- |
| Average Basic Shares Outstanding | 25.40M | 25.40M | 21.65M | 18.14M | 13.66M |
| Average Diluted Shares Outstanding | 25.40M | 25.40M | 21.65M | 18.14M | 13.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |